瑞信-美股-生物制药业-美国生物制药业:政治、渠道与新产品聚焦-201711-credit suisse-us pharmaceuticals industry overview

瑞信-美股-生物制药业-美国生物制药业:政治、渠道与新产品聚焦-201711-credit suisse-us pharmaceuticals industry overview

ID:8228350

大小:4.53 MB

页数:39页

时间:2018-03-11

瑞信-美股-生物制药业-美国生物制药业:政治、渠道与新产品聚焦-201711-credit suisse-us pharmaceuticals industry overview_第1页
瑞信-美股-生物制药业-美国生物制药业:政治、渠道与新产品聚焦-201711-credit suisse-us pharmaceuticals industry overview_第2页
瑞信-美股-生物制药业-美国生物制药业:政治、渠道与新产品聚焦-201711-credit suisse-us pharmaceuticals industry overview_第3页
瑞信-美股-生物制药业-美国生物制药业:政治、渠道与新产品聚焦-201711-credit suisse-us pharmaceuticals industry overview_第4页
瑞信-美股-生物制药业-美国生物制药业:政治、渠道与新产品聚焦-201711-credit suisse-us pharmaceuticals industry overview_第5页
资源描述:

《瑞信-美股-生物制药业-美国生物制药业:政治、渠道与新产品聚焦-201711-credit suisse-us pharmaceuticals industry overview》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库

1、USPharmaceuticalsPolitics,PipelineandNewProductsinFocus;PreferJNJ,MRKandAGNforLarge-Caps;ALKS,AIMTandMYOKinSMIDBottomLine:Inthefinalmonthsof2017,weanticipateinvestorswillcontinuetowatchmacroissuesNovember2017suchasdrugpricingandcorporatetaxreform,althoughmucho

2、fthefocusisnowontheindividualcompanystoriesandwhichnamesarebestpositionedfor2018.The3Q2017earningscyclewasatoughonebut,overall,webelievesentimentonthegroupremainsrelativelyrobustwithnoiseondrugRESEARCHANALYSTSpricingsidefarbelowwhereithasbeenandinvestorscautio

3、uslyoptimisticonthepossibilityofcorporateVamilDivan,MDtaxreform.Dependingonhowtheseissuesplayout,itcouldalsoleadtoincreasedexcitementaround(212)538-5394potentialbusinessdevelopmentinthesector,aswebelievemostofourlargecapcompaniesarestillvamil.divan@credit-suis

4、se.comwaitingforfurtherclarityontheseissuesbeforeannouncingtransformativedeals.Ontheproductsidewehaveimportantdatareleasesupcominginlargemarketssuchasoncology/immuno-oncology,rheumatoidarthritisandpsoriasis,aswellasinmorespecializedmarketssuchaspeanutallergy.M

5、ichaelV.Morabito,Ph.D.(212)325-7298JNJthecleanestnameinamessylargecapspace.JNJ’sstockhasperformedwellbutweseeroommichael.morabito@credit-forfurtherupside,drivenbythePharmaceuticalsSegmentandspecificallyproductssuchasXarelto,suisse.comDarzalex,Imbruvica,andthes

6、chizophreniafranchise.WealsolikeMRKgivenourbullishviewontheimmuno-oncologyspaceandMRK’spositioninthatspace.Weacknowledge,however,following3Q2017earningsandthedecisiontopushoutthetimelinesforKEYNOTE-189thatthereisalackofBarbaraKoteiexcitementandcatalystsaroundt

7、hename,whichcouldlimitnear-termupside.WealsolikeAGNand,(212)538-8119whilesentimentonthenameremainssplit,weassumeclarityontheheadwindstothebasebusinessbarbara.kotei@credit-suisse.com(alongwithreducedexpectationsonthesame)shouldallowforattentiontoshifttooptional

8、ityinthepipelinein2018,especiallyoncewehavemoreformal2018financialguidancefromthecompany.DuaaMohamedSeeopportunitiesinSMIDcap,ledbyALKS,AIMTandMYOK.Vivitrolremainsanunderappreciate

当前文档最多预览五页,下载文档查看全文

此文档下载收益归作者所有

当前文档最多预览五页,下载文档查看全文
温馨提示:
1. 部分包含数学公式或PPT动画的文件,查看预览时可能会显示错乱或异常,文件下载后无此问题,请放心下载。
2. 本文档由用户上传,版权归属用户,天天文库负责整理代发布。如果您对本文档版权有争议请及时联系客服。
3. 下载前请仔细阅读文档内容,确认文档内容符合您的需求后进行下载,若出现内容与标题不符可向本站投诉处理。
4. 下载文档时可能由于网络波动等原因无法下载或下载错误,付费完成后未能成功下载的用户请联系客服处理。